3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myeloid, Acute
17
Myelodysplastic Syndromes
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Hematologic Neoplasms
9
Myeloproliferative Disorders
8
Multiple Myeloma
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Hodgkin Disease
7
Lymphoma, Non-Hodgkin
6
Graft vs Host Disease
6
Waldenstrom Macroglobulinemia
5
Lymphoma
5
Burkitt Lymphoma
5
Recurrence
4
Primary Myelofibrosis
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Lymphoma, Mantle-Cell
4
Leukemia, Prolymphocytic
4
Leukemia, Myelomonocytic, Chronic
4
Skin Neoplasms
3
Sarcoma
3
Rhabdomyosarcoma
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Biphenotypic, Acute
3
Leukemia
3
Bronchiolitis Obliterans Syndrome
3
Interventions
Mitomycin
2
tislelizumab
1
molgramostim
1
cryoprecipitate coagulum
1
Tacrolimus
1
Standard of Care
1
Specimen Handling
1
Sirolimus
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Hyperthermic Intraperitoneal Chemotherapy
1
Fluorouracil
1
CTLA-4 Antigen
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pseudomyxoma Peritonei
×
Sirolimus
×
1 year
×
Clear all
NCT06084780
2026-04-09
TRANSCAPE
Case Comprehensive Cancer Center
Phase 2
Not yet recruiting
20 enrolled